General
FDA approves new indication for empagliflozin
 

FDA approves new indication for empagliflozin

Shared by:

 
The US Food and Drug Administration (FDA) has approved empagliflozin for adult patients with type 2 diabetes (T2D) and coexisting cardiovascular disease (CVD), making it the first diabetes drug approved to reduce the risk of cardiovascular death in this population.
 
specialty.mims.com
 
15 Dec 2016 - General
 
EMPA-REG OUTCOME provides data to support the long -term use of empagliflozin,as well as strong evidence for a reduction in cv risk. The cv benefits of empagliflozin occurred early in the trial (within 30 days) and continued throughout the study. Gen...
 (Total 45 words)
Finally, the drug Empagliflozin is approved by the US Food and Drug Administration (FDA) for adult patients who are suffering from type 2 diabetes mellitus and co-existing cardiovascular diseases. it is the first diabetes drug that is approved to red...
 (Total 57 words)